Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

p>

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may have important competitive advantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has completed a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second- generation MEK inhibitor for the treatmen
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Medicare Drug Plan Still Needs Work 52454 1Medicare Drug Plan Still Needs Work 52454 2Medicare Drug Plan Still Needs Work 52454 3Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 1Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 2Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 3Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 4Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 5Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 6Schering Plough Announces U S Filing of Mometasone Furoate Formoterol Fumarate Combination for the Maintenance Treatment of Asthma 4767 7NCPA 3A White House Has Ideas on How to Ration Health Care 52448 1NCPA 3A White House Has Ideas on How to Ration Health Care 52448 2
...ral formulation demonstrates 240% improvement in,b...blet and different,absorption characteristics, El...lic Conference Call to discuss results and future ...July 28 Emisphere,Technologies, Inc. (Nasdaq: EM...strating a new, more bioavailable oral form Vitami...
... 28 Cardium Therapeutics,(Amex: CXM ) announced ...edical Officer to lead the Company,s late-stage cl...Repair Company for the MATRIX Phase 2b,clinical st...didate for the,treatment of diabetic ulcers, and t... its Generx product candidate as a potential treat...
Other Medicine Technology:Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 4Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 2Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 3Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 4Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 5
(Date:12/6/2009)...olunteer organizations and members of the communit...ystem in West Los Angeles, will once again create ...d to soar to more than 5,000 veterans, active mili... (PRWEB) December 6, 2009 -- Voluntee...ooperation with the Greater VA Healthcare System i...
(Date:12/5/2009)CAPE TOWN, South Africa, December 5 The first Football,for Hope Centre in Khayelitsha in the outskirts of Cape Town opened its doors,today (5 December 2009). FIFA President Joseph S. Blatter was join
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
Breaking Medicine News(10 mins):Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2
... When your antidepressant medication does not work... the same class or should you try an antidepressan...ion" This is the question asked by researchers in...oms of major depressive disorder that do not respo...
...esignations, WASHINGTON, March 25 Bridges to Exc...rd physicians for delivering high-quality,care, an...Incentive and,Reward Program Endorsement and the B...E Incentive and Reward,Program Endorsement, the fi...
..., Inc., the leader,in the development of devices f...unced today CE Mark approval for its MitraClip(R) ...ailable device which enables a,non-surgical option...and the second most common in Europe, affecting mi...
...geon General,s national tour to, highlight communi...rograms, PHILADELPHIA, March 25 In the United St...olescents - 17.1 percent of people ages 2,to 19 ye..., high cholesterol and Type 2 diabetes., In an ef...
...yopia or shortsightedness reveals that people who ... , We have literally busted the myth that people ...r personality characteristics. They are more like...lia. , Myopia or shortsightedness is a complex ey...
...erdal Medical,Corporation announces a strategic re...ation. MedAssets Supply Chain Systems has awarded ...tion and Therapy Products." The,contract is effect...ccounts Manager states, "Our,relationship with Med...
Other Medicine News:Health News:Treating SSRI-resistant depression 2Health News:First Health Plans Receive Bridges to Excellence Endorsement and Certification 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 3Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 4Health News:U.S. Surgeon General to Keynote Special Childhood Obesity Prevention Presentation in Philadelphia 2Health News:Mythbusted -- people who wear glasses aren't geeks 2Health News:Laerdal Medical Announces Strategic Relationship 2
MULTIFIRE ENDO GIA™ 30 (Single Use Loading Units (SULU's) with Titanium Staples)
...racic Endoscopic Linear Cutter has application in ...cal procedures for transection, resection, and/or ...e line buttressing materials such as bovine perica... a total of eight firings. Different cartridges of...
ENDOPATH ETS Compact-Flex45 Articulating Linear Cutters
ENDO CLIP II 10 mm Pistol Grip (Single Use Clip Applier With Super Interlock Titanium Clips)
Medicine Products: